CALL/NOVO-NORDISK B/2000/0.1/20.09.24 | Real-time BOERSE MUENCHEN 11:57:12 12/06/2024 pm IST | ||
| 0.009 EUR | +80.00% |
|
| Current month | -37.50% | ||
| 1 month | +25.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 12/24/12 | 0.009 | +80.00% |
| 11/24/11 | 0.005 | -64.29% |
| 10/24/10 | 0.014 | +180.00% |
| 07/24/07 | 0.005 | -58.33% |
| 06/24/06 | 0.012 | -7.69% |
Real-time BOERSE MUENCHEN
Last update June 12, 2024 at 11:57 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GQ4V3V |
| ISIN | DE000GQ4V3V8 |
| Date issued | 13/09/2023 |
| Strike | 2,000 kr |
| Maturity | 20/09/2024 (100 Days) |
| Parity | 10 : 1 |
| Emission price | 0.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.122 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.1 € |
| Spread % | 90.91% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
982
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.35%
- Stock Market
- Warrants
- Warrant
